Monograph Details
|
|
Cardiovascular System
> CHF and arrhythmias
|
|
TAMBOCOR |
| Manufacturer |
|
Graceway Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Class IC antiarrhythmic. |
| Generic Name |
|
Flecainide acetate 50mg, 100mg+, 150mg+; tabs; +scored. |
| Indications |
|
Documented, life-threatening ventricular arrhythmias. Paroxysmal supraventricular tachycardias (PSVT), paroxysmal atrial fibrillation/flutter (PAF) in patients without structural heart disease. |
| Children |
|
<18yrs: not recommended. |
| Adults |
|
Sustained ventricular tachycardia: Initiate in hospital; initially 100mg every 12 hrs; may increase by 50mg twice daily at 4 day intervals; max 400mg/day. PSVT or PAF: 50mg every 12 hrs; may increase by 50mg twice daily at 4 day intervals; max 300mg daily. CrCl ≤35mL/min per 1.73m2: Initially 100mg once daily or 50mg every 12hrs. |
| Contraindications |
|
2nd- or 3rd-degree AV block or right bundle branch block associated with left hemiblock, unless paced. Chronic atrial fibrillation. Cardiogenic shock. Recent MI. |
| Precautions |
|
Verify benefits outweigh risks; see literature. Heart failure or myocardial dysfunction. Sick sinus syndrome. Pacemaker patients. Correct potassium imbalances before use. Severe renal or hepatic impairment, concomitant amiodarone or reduced myocardial function: monitor plasma level. Discontinue if heart block occurs unless paced. Discontinue if liver dysfunction, blood dyscrasias occur. Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Interactions |
|
Increased digoxin toxicity. May potentiate negative inotropic effects of β-blockers. Potentiated by cimetidine. Antagonized by phenytoin, phenobarbital, carbamazepine. Avoid disopyramide, verapamil, nifedipine, diltiazem, other negative inotropics. ½ dose when given with amiodarone. |
| Adverse Reactions |
|
Dizziness, visual disturbances, dyspnea, headache, fatigue, palpitations, chest pain, asthenia, tremor, edema, GI upset, new or exacerbated arrhythmias, heart failure, cardiac arrest, conduction defects. |
| How Supplied |
|
Tabs—100 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
